This review summarizes current evidence on advanced imaging and theragnostic strategies in prostate cancer, highlighting the role of molecular radiotracers, PSMA-targeted therapies, integrative imaging–biomarker approaches, and AI-driven tools in advancing precision oncology, supported by emerging integrative models that enable personalized risk assessment and therapeutic decision-making. Here, FOLH1 is linked to prostate cancer.